

































































Impact of a telemonitoring intervention
in patients with chronic heart failure
in Germany: A difference-in-difference
matching approach using real-world data
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Abstract
Introduction: The aim of this study was to evaluate the effects of a non-invasive telemonitoring intervention on
mortality, healthcare costs, and hospital and pharmaceutical utilisation in patients with chronic heart failure (CHF) of
a large statutory health insurer in Germany.
Methods: In a retrospective observational cohort study using real-world data, we assessed differences between 635
patients who received a telemonitoring intervention versus 635 receiving usual care covering 36 months after inter-
vention. We used propensity score matching on a set of 102 parameters collected in the 24-month pre-intervention
period to correct for observed differences, as well as difference-in-difference (DiD) estimators to account for unob-
served differences. We analysed the effect of the intervention for up to three years on (i) all-cause mortality; (ii) costs
(i.e. inpatient stays, ambulatory care, pharmaceuticals, and medical aids and appliances); and (iii) healthcare utilisation (i.e.
length and number of hospital stays, number of prescriptions).
Results: DiD estimates suggest lower inpatient costs of the telemonitoring group of up to e1160 (95%
confidence interval (CI): –2253 to –69) in year three. Ambulatory care costs increased significantly in all three years
up to e316 (95% CI: 1267 to 505) per year. Telemonitoring had a positive effect on survival (hazard ratio¼ 0.71; 95% CI:
0.51 to 0.99) and increased the number of prescriptions for diuretics. Effects were more prominent for patients with
severe CHF.
Discussion: The study suggests that the telemonitoring intervention led to a significant decrease in mortality and a shift
in costs from the inpatient to the ambulatory care sector 36 months after intervention.
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Introduction
Chronic heart failure (CHF) is a cardiovascular disor-
der with a high incidence worldwide (5–10 cases per
1000 persons/year).1 It is one of the most frequent diag-
noses in Germany2 and the most common diagnosis
during hospital admission in the developed world for
patients aged 65þ.3 This leads to high costs, mostly due
to repeated hospitalisations.4 Reported mortality rates
vary substantially, but are generally high,5 especially
after recent hospitalisations.1,6
Telemonitoring is one approach for tackling high
costs and strengthening patient autonomy. It aims to
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facilitate disease management by frequently monitoring
parameters such as weight or blood pressure, thereby
detecting early changes in patients’ condition that
might warrant intervention. Home telemonitoring can
be beneficial in other dimensions – for example, reduc-
ing physical contacts of vulnerable patient groups
during the global COVID-19 pandemic.7 It can also be
used to detect possible emergencies, such as cardiac pul-
monary oedema and facilitate their timely management.
While not all studies report significant positive effects on
all-cause mortality, several trails have shown that tele-
monitoring is beneficial, especially in reducing all-cause
mortality and CHF-related hospitalisation.8–11 Most
studies have focused on mortality and hospitalisations,
fewer have investigated costs or multiple outcomes. In
those that have investigated costs, with few exceptions,12
the intervention period has usually been short, limiting
information about the long-term effects.10
In this study, we aim to address this gap by evalu-
ating the effects of a non-invasive home telemonitoring
intervention on all-cause mortality, healthcare costs,
healthcare utilisation, and pharmaceutical prescribing
in a large population over three years. We rely on
individual-level data from a large statutory health
insurer in Germany (IKK Südwest) and use a two-
stage approach combining propensity score matching
(PSM) with difference-in-difference (DiD) estimation
to correct for observed and unobserved differences.13,14
In total, we compare 635 individuals for 36 months
after they started the telemonitoring intervention with
635 matched individuals who received usual care.
Methods
Design and sample
Using a retrospective cohort design, we compare
patients with a history of CHF who had received
either usual care as control group (CG) or usual care
plus a telemonitoring intervention as intervention group
(IG) in a real world setting. Usual care is the standard
treatment delivered by the German healthcare system,
which, compared to other countries, is very fragmented.
The care for CHF patients is usually delivered by a gen-
eral practitioner and a cardiologist, both in private prac-
tices, which are expected to deliver guideline concordant
care.15 The observation period of five years began with a
baseline comparison 24 months before the intervention
started and lasted for 36 months after the start (Figure
1). Enrolment was staggered in three-month increments
between Q2/2012 and Q4/2014. We base our analysis on
claims data from a large statutory health insurer in
Germany comprising individual-level demographics, as
well as data on all-cause mortality; costs to the payer;
inpatient and ambulatory care visits including all diag-
noses (ICD-10-GM); prescriptions of ambulatory care
pharmaceuticals; and medical aids and appliances paid
for by the insurer. We observed patients from Q1/2010
through Q2/2017.
We considered only CHF patients (18 years) with
an existing diagnosis to be eligible and, therefore,
screened all individuals two years before the start of
the intervention in both the claims data for CHF-
related hospitalisations and additionally related ambu-
latory diagnoses. Newly CHF-diagnosed patients are
not included. Patients with severe terminal illnesses or
conditions that made telemonitoring impractical or
impossible, such as dementia or dialysis, were excluded.
Online Appendix A provides the full criteria list.
The health insurer identified eligible patients in the
claims data via pre-defined ICD-10 diagnoses.
These were randomly assigned to either IG or CG.
Those in the IG were contacted by the health insurer
and given information on the programme to decide on
participation. The health insurer covered all costs of
the programme. Before final enrolment, participating
Figure 1. Research design, with a 24-month pre-intervention observation used for the PSM matching and the 36-month follow-up.
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physicians re-assessed the IG candidates for eligibility and
applied exclusion criteria that could not be observed in the
claims data – for example, if the patients lack German
language skills. All participants in the IG provided written
consent, while the CG continued usual care. Universit€at
Hamburg granted ethical approval.
Telemonitoring intervention
The telemonitoring intervention, which was provided
on top of usual care, was non-invasive and designed
to help CHF patients manage their disease by regularly
monitoring relevant parameters within their usual phy-
sician network. At a minimum, patients who received
the telemonitoring intervention were equipped with an
electronic scale that reminded them to weigh them-
selves daily. Depending on patients’ comorbidities,
patients also receive a blood pressure monitor (hyper-
tensive heart disease, daily transmission), a 12-channel
electrocardiogram (ischemia or arrhythmia, monthly
transmission or on-demand), or both. Data from all
devices were transmitted automatically to the telemo-
nitoring centre. If patients were non-compliant (e.g. not
transmit measures), they were contacted.
The backbone of the telemonitoring system was an
electronic patient record that was updated in real time
and made available to patients’ physicians. The dedi-
cated telemonitoring centre, run by an external organi-
sation and staffed with at least one physicians and
several nurses, contacted patients or their physicians
in case the measured data was not transmitted or devi-
ated from the pre-set boundary (defined by default as
1.5 kg or 2% weight deviation to the day before, sys-
tolic blood pressure >160mmHG or <90mmHG, dia-
stolic blood pressure >100mmHg or <50mmHg, or a
heart frequency >100 bpm or <50 bpm). Both the
patients and the physicians could seek advice 24/7
from the centre’s specialists. Additionally, the telemo-
nitoring centre performed standardised follow-up calls
with the patient every four to six weeks to provide edu-
cation on CHF-related topics and advice on self-
management.
Statistical analysis
We used a matching DiD approach13,14,16 to address
selection bias into the program by patients or physi-
cians. First, we applied PSM17 and matched on pre-
intervention observables to eliminate bias arising
from factors that predicted participation in the inter-
vention. We used nearest neighbour (1:1) matching,
within a caliper width of 0.01, to align the IG and
CG over 102 observable baseline characteristics for
year one and two before the enrolment, to follow dis-
ease progression. We matched on variables observed 24
months before the start for the IG or, for the CG, 24
months before 1 January 2013. We matched for age,
sex, months since last hospital stay, retirement status,
and residence. For comorbidity, we used the 16
Charlson comorbidity groups,18,19 22 pharmaceutical
groups, based on the Anatomical Therapeutic
Chemical (ATC) Classification System, shown to be
relevant in the treatment of heart diseases (see online
Appendix C)15,20 and CHF severity based on the coded
New York Heart Association (NYHA) classes.
Furthermore, we considered healthcare costs and uti-
lisation before the start of the intervention. In our main
specification, we excluded patients who died during the
observation period from the DiD analysis before the
matching because costs escalate before the end of life
and may disturb the results if the intervention has an
effect on survival.21
Using the best matching approach is of utmost
importance to avoid bias. Therefore, we applied two
sensitivity analyses: including deceased patients and
entropy balancing.22
To avoid bias, we analysed healthcare costs and uti-
lisation using an additional DiD approach to account
for unobservable differences.23,24 We compared the dif-
ference in costs and utilisation one year before the start
of the intervention between CG and IG with the differ-
ence in costs and utilisation between the two groups in
year one, year two, and year three after enrolment to
determine the effect of the intervention (Figure 1). DiD
allows us to take account for unobserved differences
between the groups that could not be captured by
PSM, such as physical activity and smoking behaviour.
We measured costs from the payer perspective in Euros
at 2015 values, categorised as inpatient, ambulatory,
pharmaceutical, and medical aid and appliance.
Inpatient costs were winsorised at e100,000 per year to
limit distortion by outliers.
To analyse whether any effect of the intervention
might differ depending on whether patients had mild
or severe CHF, we stratified between different NYHA
groups, defining CHF in patients coded with NYHA
III–IV as severe, and with NYHA I, II and unknown
as mild.
We performed the survival analysis on the full
sample with a similar matching using Kaplan–Meier
estimates and tested differences in survival with a log-
rank test and a Cox proportional hazard model. We
used SAS 9.4 for data processing and STATA 15.1 for
statistical analysis.
Results
Table 1 and online Appendix C give an overview of the
two groups before matching. In total, 738 patients were
in IG and 869 in the CG. Patients in the IG were, on
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average, younger (63.8 vs 64.7 years) and more likely
female (71.0% vs 67.1%), but had similar NYHA clas-
ses. Disease progression before the intervention dif-
fered substantially between the two groups: patients
in the IG had more (1.5 vs 0.8) and longer (12.3 vs
5.6 days) hospital visits in the year before the interven-
tion compared to the CG. We used risk adjustment for
each of the two years before the start of the interven-
tion to account for differences in morbidity, costs, and
disease progression.
Matching
PSM successfully decreased the pre-intervention differ-
ences between the IG and CG in the 635 matched pairs
(Table 1). A detailed list of matching variables can be
found in the online Appendix C. We assessed the qual-
ity of matching using the standardised difference17 and
defined a negligible difference as <10%.25 Before
matching, mean standardised difference over all varia-
bles was 10.0%, and 32 variables had values >10%.
Table 1. Pre- and post-matching characteristics of the study population.
Before matching After matching
Patient characteristics CG IG Std diff CG IG Std diff
Age (years) 64.7 63.8 7.1 64.5 64.4 1.4
Age2 (years) 4390.0 4212.0 10.8 4321.2 4294.0 1.7
Sex (1¼ female) 67.1 71.0 –8.3 66.8 69.3 –5.4
Pensioner (1¼ pensioner) 63.7 63.2 1.0 64.4 64.6 –0.3
Urban 20.7 21.4 –1.9 23.6 21.9 4.1
Rural 60.1 59.6 0.9 56.9 59.4 –5.1
Month since last hosp. 16.3 10.5 60.6 12.1 12.0 1.3
Disease severity (NYHA classification)
Class not coded 37.4 34.4 6.3 34.0 36.7 5.5
NYHA Class unspecified 16.1 15.4 2.0 18.3 16.9 3.7
NYHA Class I 2.8 4.6 9.6 3.8 3.9 0.8
NYHA Class II 18.0 18.1 0.2 18.6 18.4 0.4
NYHA Class III 13.7 15.7 5.6 15.0 14.6 0.8
NYHA Class IV 11.9 11.8 0.3 10.4 9.4 3.1
Costs in t–1 (EUROS)
Ambulatory care 730.1 807.4 –12.8 858.6 811.4 7.4
Inpatient 3142.1 7668.3 –50.0 4845.7 5077.7 –3.0
Pharmaceuticals 1265.5 1368.3 –4.8 1316.0 1338.6 –1.3
Medical aids and appliances 309.9 318.3 –0.9 293.4 303.2 –1.3
Costs in t–2 (EUROS)
Ambulatory care 715.5 692.3 4.0 757.7 749.6 1.2
Inpatient 4941.8 4271.6 8.6 5055.8 4793.7 3.3
Pharmaceuticals 1232.8 1092.3 5.8 1166.3 1200.7 –1.8
Medical aids and appliances 217.3 237.5 –2.9 220.4 231.1 –1.7
Utilisation in t–1
Number of hospital visits 0.76 1.52 –56.0 1.20 1.19 0.5
Length of stay (days) 5.61 12.34 –47.1 9.16 8.74 3.4
Utilisation in t–2
Number of hospital visits 1.17 0.92 19.8 1.14 1.07 5.5
Length of stay (days) 9.06 7.10 15.0 8.98 8.08 6.8
Comorbidity and Pharmaceutical groups in t–1
Charlson groups 4 of 17 with std diff> 10 0 of 17 with std diff> 10
Pharmaceutical groups 9 of 22 with std diff> 10 0 of 22 with std diff> 10
Comorbidity and Pharmaceutical groups in t–2
Charlson groups 0 of 17 with std diff> 10 0 of 17 with std diff> 10
Pharmaceutical groups 10 of 22 with std diff> 10 0 of 22 with std diff> 10
N 738 869 635 635
Note: unless specified otherwise, numbers are in percent. Deceased patients are excluded. All costs (ambulatory, inpatient, pharmaceuticals, medical
aids and appliances) reported are 2015 Euros and refer to all costs (not just CHF-related) reimbursed by the health insurer. Details on the Charlson
and Pharmaceutical groups can be found in online Appendix C.
Std diff: standardised difference; CG: control group; IG: intervention group; NYHA: New York Heart Association. Pharmaceutical groups follow
Koehler et al.20
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Matching reduced mean standardised difference to
3.4%, and yielded standardised differences <10% for
all variables. Stratifying the overall sample into differ-
ent NYHA classes lead to 157 matched pairs in the
severe and 478 in the mild group.
Survival
The results of the Kaplan–Meier survival estimates and
a Cox proportional hazard model are shown in Figure 2
and Table 2.
Kaplan–Meier estimates suggest that the survival of
individuals in the IG was better than in the CG (strat-
ified logrank test p¼ 0.029). This is reflected in the
results of the Cox proportional hazards model, which
shows a statistically significant 29% lower risk of dying
in the IG (hazard ratio: 0.71; 95% confidence interval
(CI): 0.51 to 0.99; p¼ 0.04). We corrected for potential
confounding effects by entering age and the NYHA
class in the Cox model, which both had also a signifi-
cant effect.
Comparing the Kaplan–Meier survival estimates in
the subgroup analysis, we found that patients with
severe CHF had a higher mortality rate compared to
those with mild CHF, and that the intervention
appeared to have a greater effect in the former than
the latter (Figure 3).
Healthcare costs
We analysed the effect of the telemonitoring interven-
tion on four cost categories using the matching DiD
approach (Table 3). The model compares the difference
between the IG and CG in the baseline period (i.e., one
year before the intervention) with the difference
between both groups for each year of the three-year
intervention period (defined as year one, two, or
three after intervention). The difference in inpatient
costs between the IG and CG in year one and two of
the intervention did not differ significantly from the
difference observed in the year before the intervention
(216e; 95% CI: 1273 to 841; p¼ 0.69, and 54e; 95%
CI: 877 to 985; p¼ 0.91). However, we did observe a
significant difference for year three of the intervention
(1161e; 95% CI: 2252 to 69, p¼ 0.04). Compared
to the year before the invention, the difference in ambu-
latory care costs between the IG and CG was signifi-
cantly higher for each of the three years, on average by
e284. Compared to baseline, the difference in pharma-
ceutical costs between the IG and CG increased, with
significant results in year two. For medical aids and
appliances, the differences were small and insignificant.
Table 4 shows the results for patients with mild or
severe CHF. The effect of the intervention on costs
appears to have been greater in the latter group, result-
ing in a higher reduction of inpatient costs compared to
the CG and the baseline period; however, only signifi-
cant for year two. In contrast, significant higher cost
differences in year two compared to the baseline differ-
ence were seen in patients with mild CHF compared to
Figure 2. Kaplan–Meier survival estimates after PSM differen-
tiating between IG and CG, and the stratified logrank test on
equality of survival curves.




NYHA Class 1.254 (4.53)**
N 1460
HR: hazard ratio; NYHA: New York Heart
Association. Z-statistic in parenthesis.
*p< 0.05.
**p< 0.01.
Figure 3. Kaplan–Meier survival estimates for subgroups after
PSM differentiating between IG and CG for mild (NYHA class I–II
and unspecified) and severe heart failure (NYHA class III–IV).
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the CG. Furthermore, the magnitude of the increase in
the differences of ambulatory care costs was higher in
each of the three years for the IG with severe CHF,
compared to the baseline difference.
Healthcare utilisation
Table 3 presents the DiD estimates of the intervention
on the patients’ use of inpatient care and the
Table 3. Difference-in-difference (DiD) estimates after propensity score matching.
t1 t2 t3
Cost (Euros)
Inpatient –216 (539) 53 (475) –1161** (557)
Ambulatory care 275*** (42) 261*** (69) 316*** (97)
Pharmaceuticals 162 (102) 216** (98) 46 (146)
Medical aids and appliances 1 (50) 36 (74) –76 (73)
Utilisation (days)
Number of hospital stays 0.07 (0.079) 0.04 (0.09) –0.10 (0.09)
Length of stay 0.35 (0.93) 1.49* (0.77) –0.25 (1.18)
Pharmaceutical prescriptions
Diuretics 0.75*** (0.16) 1.08*** (0.18) 1.00*** (0.18)
Beta-blockers 0.16 (0.14) 0.00 (0.15) 0.20 (0.15)
Agents affecting RAS 0.23 (0.15) 0.08 (0.16) 0.10 (0.17)
N 1270 1270 1270
Note: DiD estimates including all covariates of the matching approach of intervention group (usual careþ telemonitoring intervention) vs control
group (usual care), comparing one year before with year 1–3 after the intervention. All costs (ambulatory, inpatient, pharmaceuticals, medical aids and
appliances) reported are 2015 Euros and refer to all costs (not just CHF-related) reimbursed by the health insurer.
PSM: propensity score matching; RAS: renin–angiotensin system.












t1 t2 t3 t1 t2 t3
Costs (EUR)
Inpatient –327 (612) 806* (490) –884 (620) 88 (1144) –2227* (1178) –2018 (1225)
Ambulatory care 244*** (49) 225*** (83) 238** (109) 365*** (76) 365*** (106) 546*** (202)
Pharmaceuticals 156 (106) 118 (77) 96 (132) 190 (260) 518 (327) –95 (421)
Medical aids/appliances –55 (52) 30 (67) –101 (83) 169 (120) 49 (207) –1.2 (144)
Utilisation
Number of hospital stays 0.02 (0.09) 0.06 (0.10) –0.13 (0.10) 0.19 (0.17) –0.03 (0.20) –0.02 (0.18)
Length of stay 0.01 (1.1) 2.56*** (0.83) 0.14 (1.17) 1.27 (1.91) –1.83 (1.77) –1.48 (3.15)
Prescriptions
Diuretics 0.64*** (0.16) 0.84*** (0.18) 0.81*** (0.19) 1.09*** (0.40) 1.78*** (0.40) 1.58*** (0.40)
Beta-blockers 0.15 (0.16) 0.06 (0.17) 0.35** (0.17) 0.19 (0.29) –0.18 (0.30) –0.27 (0.31)
Agents affecting RAS 0.14 (0.18) –0.09 (0.19) –0.06 (0.19) 0.47* (0.27) 0.55* (0.29) 0.58* (0.30)
N 956 956 956 314 314 314
Note: DiD estimates for subgroups of mild CHF (NYHA I–II þunspecified) and severe CHF (NYHA III–IV) including all covariates of the matching
approach of intervention group (usual careþ telemonitoring intervention) vs control group (usual care), comparing one year before with year 1–3 after
the intervention. All costs (ambulatory, inpatient, pharmaceuticals, medical aids and appliances) reported are 2015 Euros and refer to all costs (not just
CHF-related) reimbursed by the health insurer.
RAS: renin–angiotensin system: NYHA: New York Heart Association.
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prescription of CHF-relevant pharmaceuticals.26
Neither the number of hospital stays nor their length
appeared to be consistently affected by the intervention
over the three-year period. Only a significant increase
in the length of stay of 1.5 days (95% CI: –0.01 to 3.00;
p¼ 0.05) could be observed for the IG in year two after
the intervention.
The difference in the number of pharmaceuticals
prescribed according to the relevant guidelines
increased for the IG in each of the three years of the
intervention compared to the baseline, especially for
diuretics (ATC class: C03). Differences in the number
of diuretic prescriptions increased significantly by 0.8
prescriptions per year (95% CI: 0.44 to 1.01; p< 0.01)
in year one for the IG, followed by an additional
increase to 1.1 prescriptions in year two (95% CI:
0.73 to 1.42; p< 0.01), and 1.0 prescriptions in year
three (95% CI: 0.65 to 1.4; p< 0.01). The difference
in the number of prescriptions of beta-blockers (ATC
class: C07) and agents acting on the renin–angiotensin
system (ATC class: C09) increased insignificantly in the
IG over the observation period.
We see in Table 4 that patients in the IG with severe
CHF appeared to be more affected than patients with
mild CHF, leading to a shorter length of stay in the
former in years two and three, whereas the group with
mild CHF had a longer length of stay in year two com-
pared to baseline. Again, hospital visits seem not to be
affected. Looking at the prescriptions shows an
increase in the difference of the number of diuretics
(ATC C03) prescribed to patients in the IG in both
severity groups. We observe higher differences in pre-
scription rates for beta-blockers in patients with mild
CHF and for agents affecting the renin–angiotensin
system in patients with severe CHF compared to the
baseline year differences.
The results of the entropy balancing approach and
the analysis including the deceased were comparable in
size and magnitude, with few exceptions (online
Appendix B).
Discussion
In this retrospective observational cohort study using
real-world data, we analysed the impact of a telemoni-
toring intervention in 635 matched patients with CHF
on all-cause mortality, healthcare costs and utilisation,
and guideline-concordant ambulatory care prescribing
over 36 months. We found a significant positive
impact of the intervention on mortality. The risk of
dying in the IG was 29% lower than in the CG, an
effect similar in magnitude to that reported in a meta-
analysis of several international randomised controlled
trials (RCTs), a Cochrane review,8,11 and two large
German observational studies.27,28
In terms of costs, our study revealed two principal
effects: whereas the costs of inpatient care were lower
in the IG, especially in the third year of the intervention,
the costs of ambulatory care were significantly higher in
the IG in each observation year. The lower inpatient
costs we observed compared to the CG in year three
offset the higher ambulatory care costs over the full
observation period. Similar to other observational stud-
ies,29 our findings suggested that the intended shift from
inpatient to ambulatory care was successful.
Regarding healthcare utilisation, we did not find any
significant effects, unlike most RCTs.8 However, our
findings were in line with other observational studies.28,30
Our study advances the current literature in several
aspects. Our two-stage approach to risk adjustment cor-
rects for observed and unobserved characteristics.
Although this is highly suitable for analysing the effects
of complex interventions in real-world conditions,14,16 it
has been used rarely to date.28,30 For observed character-
istics, we matched on a large set of 102 pre-intervention
variables to correct for a wide range of observable char-
acteristics. We accounted for unobserved differences by
using a DiD approach. Most studies use fewer variables
for matching and did not correct for unobserved charac-
teristics, potentially leading to biased results.
Furthermore, the combination of the four outcomes
and a comparably large observational period is unique
given that most studies focus on either clinical outcomes,
such as mortality, or a single cost category. This implies
that these studies cannot show the interrelationships
between the different dimensions while focussing on
short-term results, which may lead to wrong decisions
at the health policy level. Finally, we complement evi-
dence from RCTs by providing real-world evidence,
which is important to show external validity.31
This study is not without limitations. Chief among
these is its reliance on claims data, which provide a rich
dataset but do not allow analysing factors, such as clin-
ical parameters (e.g. left ventricular ejection fraction),
if patients already have implanted medical devices (e.g.
pacemakers) and differentiate between healthcare pro-
viders. While the IG was additionally screened for eli-
gibility for telemonitoring, the CG could not be
screened, which may bias enrolment. While the external
validity of our findings is relatively high due to our use
of real-world data and a large IG, randomisation
would further improve internal validity.
Further research may add to our findings by com-
bining clinical with claims data as this can add a
number of important clinical or surrogate endpoints.
Conclusion
We evaluated the impact of a telemonitoring interven-
tion on all-cause mortality, healthcare costs, healthcare
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utilisation, and pharmaceutical prescribing. Using
PSM and DiD, we followed 635 matched pairs of
patients with CHF during a three-year intervention.
We were able to show that telemonitoring can have
substantial positive effects on mortality and guideline-
concordant pharmaceutical prescribing even in the first
year of intervention and may help shift care from the
inpatient to the ambulatory care sector, especially in
year three. Our findings suggest that the benefits of
the telemonitoring intervention were greater for
severe CHF patients and underscore the need to sup-
plement RCTs with studies that use real-world data to
capture the everyday reality of health services.
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